OncoSec Medical Inc. Presents New Data At 10th Annual PEGS: The Essential Protein Engineering Summit In Boston
5/5/2014 7:10:59 AM
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its ImmunoPulse DNA-based immunotherapy to treat solid tumors, today presented preliminary experimental findings demonstrating that electroporation with DNA-based IL-12 in mice can lead to systemic anti-tumor immune responses in distant untreated lesions. These data are consistent with the previously reported findings in melanoma patients treated in the Phase 2 OMSI100 study (December 2013).
Help employers find you! Check out all the jobs and post your resume.
comments powered by